The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
VYALEV (Abbvie Pty Ltd)
Product name
VYALEV
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
232 (255 working days)
Active ingredients
foscarbidopa, foslevodopa
Registration type
New combination
Indication
For the treatment of advanced idiopathic Parkinson’s disease with severe motor fluctuations despite optimised alternative pharmacological treatment.